PT-141 vs Melanotan II

Evidence-based comparison. Updated 2026.

PT-141 is the appropriate choice for treating sexual dysfunction, as it is FDA-approved and acts centrally via MC4R to enhance arousal in both men and women. Melanotan II is a research-only compound studied primarily for skin tanning and secondarily for libido effects, with a broader and less selective receptor profile. Choose PT-141 for clinical sexual health applications and consider Melanotan II only in a research context for its melanogenic properties.

Side by side

	PT-141	Melanotan II
Evidence	AEvidenceGrade ALarge human randomised controlled trials, or FDA / major-authority approved	CEvidenceGrade CMainly animal or in-vitro studies, with limited human data
Regulatory	FDA approvedFDA approvedApproved by the US Food and Drug Administration for at least one use	Research onlyResearch onlyNo regulatory approval in any major jurisdiction. For research use only
Benefits	Treats sexual dysfunction in men and women Enhances arousal and desire Works via central nervous system (not vascular like Viagra) FDA-approved for female HSDD Effective for psychological erectile dysfunction	Stimulates melanogenesis (tanning) Tanning without UV exposure (photoprotection) Appetite suppression Libido enhancement May reduce sun damage risk
Dosage	1-2 mg mg, As needed, 45 minutes before sexual activity	250-500 mcg mcg, Daily until desired tan, then 2-3x/week maintenance
Route	Subcutaneous, Intranasal	Subcutaneous
Category	Sexual Health & Libido	Tanning & Pigmentation

Full research page

PT-141

Full research page

Melanotan II

Which should you choose

PT-141 and Melanotan II share structural similarity as melanocortin receptor agonists, but differ critically in receptor selectivity: PT-141 is optimized for MC4R to produce targeted central nervous system effects on sexual function, while Melanotan II binds non-selectively across multiple melanocortin receptors, producing broader systemic effects including skin pigmentation, appetite suppression, and libido changes.

Choose PT-141 when

FDA-approved as bremelanotide for hypoactive sexual desire disorder in premenopausal women, providing a regulatory-backed safety and efficacy profile
Targets sexual dysfunction specifically through CNS pathways, making it effective for both psychological erectile dysfunction and HSDD without vascular mechanism dependence
Higher evidence grade and more controlled clinical trial data supporting its use for sexual arousal in both men and women

Choose Melanotan II when

Research interest in melanogenesis and UV-independent skin tanning, a mechanism not shared by PT-141
Secondary appetite-suppressive effects observed in studies, which fall outside PT-141's pharmacological profile
Broader melanocortin receptor activation may be relevant for researchers studying the full spectrum of the melanocortin system

Stacking PT-141 and Melanotan II is not a common or well-studied practice, and given Melanotan II's non-selective receptor binding and research-only status, combining the two introduces unpredictable additive effects and an unclear safety profile.

Questions people ask

Do PT-141 and Melanotan II produce the same libido effects through the same mechanism?

Both peptides influence sexual function through the melanocortin system, but their receptor profiles differ meaningfully. PT-141 selectively activates MC4R in the hypothalamus to enhance dopamine-mediated sexual motivation and arousal. Melanotan II binds less selectively across MC1R, MC3R, MC4R, and MC5R, so its libido effects are a secondary consequence of broader receptor activation rather than a targeted CNS action. Research suggests PT-141 produces more consistent and predictable sexual function outcomes as a result.

How do the onset and duration timelines of PT-141 and Melanotan II compare for their respective primary effects?

PT-141 administered subcutaneously typically produces onset of sexual arousal effects within 45 minutes to 1 hour, with effects lasting approximately 6 to 12 hours in clinical studies. Melanotan II's tanning effects are cumulative and develop over repeated dosing across days to weeks rather than producing a single-dose acute effect. For libido effects specifically, Melanotan II users in research contexts have reported onset within 1 to 4 hours of administration, though this data comes largely from uncontrolled observations rather than rigorous trials.

Can Melanotan II substitute for PT-141 when the goal is treating sexual dysfunction?

Melanotan II is not an appropriate substitute for PT-141 in treating sexual dysfunction. PT-141 is FDA-approved with documented efficacy in controlled trials for HSDD and erectile dysfunction of psychological origin, while Melanotan II remains a research-only compound with no approved therapeutic indication. Melanotan II's broader receptor binding profile also produces side effects including nausea, flushing, and spontaneous erections that differ from PT-141's more targeted profile, and it lacks the regulatory oversight required for clinical use.

What are the key safety differences between PT-141 and Melanotan II that researchers and clinicians should consider?

PT-141 has an established safety profile from FDA review, with the most common adverse effects being nausea, flushing, and transient blood pressure changes. Melanotan II, as a research-only compound, carries additional concerns including reports of melanocytic nevus changes, dysregulated pigmentation, and cardiovascular effects linked to its non-selective receptor activation across multiple melanocortin receptor subtypes. The absence of phase III clinical trial data for Melanotan II means its long-term safety profile is substantially less characterized than that of PT-141.

Goal-based guides

Broader evidence guides for the goals this comparison relates to.

Best peptides for Sexual Health

Not sure which fits your research goals?

Use the goal finder

Answer three questions and get a peptide recommendation ranked by evidence grade.

Find my peptide